US M&A and equity raisings

3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

64 deals · US$76bndisclosed · Pharma · Clear

Columns
US M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Oct 2026 HCXT-2001 (investigational oral IL-23R inhibitor) PepStar TherapeuticsGileadAsset saleAnnounced–Pharma+1 Lazard
Oct 2026 Orbus Therapeutics –US WorldMedsAcquisitionCompleted–Pharma+2 Lazard
Sep 2026 Royalty participation rights in U.S. net sales of tavapadon Bain CapitalDRI Healthcare TrustAsset saleAnnounced316.0Specialty finance and leasing+2 Cravath, Swaine & Moore (buy-side)
Aug 2026 TYRVAYA (varenicline solution) nasal spray 0.03 mg ViatrisHarrowAsset saleAnnounced30.0Pharma+1 Cravath, Swaine & Moore (sell-side)
Aug 2026 Lantheus Holdings –Curium US HoldingsAcquisitionAnnounced8,000.0Radiopharmaceuticals+1 Morgan Stanley (sell-side)BofA Securities (sell-side)Solomon Partners (sell-side)Covington & Burling (sell-side)Ropes & Gray (sell-side)Jefferies (buy-side)J.P. Morgan (buy-side)PJT Partners (buy-side)Kirkland & Ellis (buy-side)Arnold & Porter (buy-side)
Aug 2026 Supernus Pharmaceuticals ––MergerAnnounced–Pharma Morgan Lewis (sell-side)Cantor Fitzgerald (sell-side)Wells Fargo Securities (sell-side)Saul Ewing (sell-side)Jefferies (buy-side)Piper Sandler (buy-side)Goodwin (buy-side)Citi (buy-side)
Aug 2026 BWXT Medical business BWX TechnologiesNordic CapitalAsset salePending800.0Radiopharmaceuticals+2 Solomon Partners (sell-side)Stikeman Elliott (sell-side)Kirkland & Ellis (buy-side)McCarthy Tétrault (buy-side)
Jul 2026 Neurimmune's royalty interest in AstraZeneca's cliramitug NeurimmuneRoyalty PharmaAsset saleAnnounced250.0Pharma+1 Goodwin (buy-side)
Jul 2026 Avere Therapeutics –Hansoh Pharmaceutical Group Co.StakeAnnounced–Biotech+2 Goodwin (buy-side)
Jul 2026 newly established entity holding Bayer's long-acting reversible contraceptives (LARC) business BayerApolloStakeAnnounced3,465.9Pharma Latham & Watkins (buy-side)Paul, Weiss (buy-side)
Jul 2026 iRenix Medical –Tarsus PharmaceuticalsAcquisitionAnnounced75.0Ophthalmology+2 Piper Sandler (sell-side)DLA Piper (sell-side)Gunderson Dettmer (buy-side)
Jul 2026 Crinetics Pharmaceuticals –Vertex PharmaceuticalsAcquisitionAnnounced10,000.0Biotech+2 Lazard (buy-side)J.P. Morgan (sell-side)Leerink Partners (sell-side)Paul, Weiss (sell-side)Morrison & Foerster (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Jul 2026 Lannett –AurobindoAcquisitionCompleted250.0Pharma+1 Raymond JamesSullivan & Cromwell (buy-side)
Jun 2026 Theravance Biopharma –ZymeworksAcquisitionPending929.0Pharma+1 Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side)MTS Health Partners (buy-side)
Jun 2026 Azora Therapeutics –Adial PharmaceuticalsAsset saleCompleted–Biotech+2 Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side)
Jun 2026 US generic and specialty pharmaceutical product portfolio of Nordic Pharma Nordic PharmaJ. MolnerAsset saleCompleted–Pharma Raymond James
May 2026 Altruix WindRose Health InvestorsFrazier Healthcare PartnersAcquisitionCompleted–Behavioral Health+1 Houlihan Lokey (sell-side)Cantor Fitzgerald (sell-side)Latham & Watkins (sell-side)Goodwin (buy-side)
May 2026 Mentari Therapeutics –InMed PharmaceuticalsAcquisitionAnnounced–Biotech+1 Wedbush Securities (sell-side)Gibson Dunn (sell-side)Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side)
May 2026 Orphai Therapeutics –Quince TherapeuticsAcquisitionCompleted–Biotech+2 Cooley (sell-side)LifeSci Capital (buy-side)Dorsey & Whitney (buy-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side)
May 2026 Catalyst Pharmaceuticals –Angelini Pharma S.p.A.AcquisitionPending4,100.0Pharma+1 J.P. Morgan (sell-side)Kirkland & Ellis (sell-side)Akerman (sell-side)Centerview Partners (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Hogan Lovells Cadwalader (buy-side)Gatti Pavesi Bianchi Ludovici (buy-side)
May 2026 Esperion Therapeutics –ARCHIMEDAcquisitionPending1,100.0Pharma+1 Latham & WatkinsCenterview Partners (sell-side)Goodwin (sell-side)Moelis & Company (buy-side)Sidley Austin (buy-side)
Apr 2026 KalVista Pharmaceuticals –Chiesi GroupAcquisitionCompleted1,900.0Pharma+2 Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side)
Apr 2026 Shionogi-Apnimed Sleep Science ApnimedShionogi & Co.AcquisitionAnnounced100.0Pharma+1 Goodwin (sell-side)
Apr 2026 Emalex Biosciences –Teva PharmaceuticalsAcquisitionAnnounced700.0Pharma+1 Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side)
Apr 2026 Organon & Co. –Sun Pharmaceutical IndustriesAcquisitionAnnounced11,750.0Pharma Morgan Stanley (sell-side)Goldman Sachs (sell-side)Sullivan & Cromwell (sell-side)Cyril Amarchand Mangaldas (sell-side)J.P. Morgan (buy-side)Jefferies (buy-side)White & Case (buy-side)AZB & Partners (buy-side)
Apr 2026 Kashiv BioSciences –Amneal PharmaceuticalsAcquisitionCompleted375.0Biotech+2 J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side)
Apr 2026 Cumberland FDA-approved commercial products and related assets Cumberland PharmaceuticalsNuvo Pharmaceuticals (Ireland) DACAsset salePending100.0Pharma VelocityHealth Securities (sell-side)Baker Donelson (sell-side)Kirkland & Ellis (buy-side)
Apr 2026 Neurona Therapeutics –UCBAcquisitionAnnounced650.0Biotech+2 Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side)
Apr 2026 US sales and distribution rights for seven Assertio branded products Assertio HoldingsCosette PharmaceuticalsAsset saleAnnounced–Pharma Gibson Dunn (sell-side)
Apr 2026 Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) Assertio HoldingsCosette PharmaceuticalsAsset saleCompleted35.0Pharma Moelis & Company (sell-side)Gibson Dunn (sell-side)
Apr 2026 Worldwide rights to Kenalog Bristol-Myers SquibbSubsidiary of Piramal PharmaAsset saleAnnounced35.0Pharma Goodwin (buy-side)
Apr 2026 Assertio Holdings –Zydus Worldwide DMCCAcquisitionAnnounced166.4Pharma Moelis & Company (sell-side)Gibson Dunn (sell-side)Longacre Square Partners (sell-side)Paul, Weiss (buy-side)
Apr 2026 Soleno Therapeutics –Neurocrine BiosciencesAcquisitionCompleted2,900.0Biotech+2 Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side)
Apr 2026 Exclusive global rights to TAK-063 (balipodect) Takeda Pharmaceutical Co.Axsome TherapeuticsAsset saleCompleted–Pharma+1 Sidley Austin (buy-side)
Apr 2026 Cumberland U.S. branded businesses Cumberland PharmaceuticalsApotexAsset saleAnnounced–Pharma Kirkland & Ellis (buy-side)
Apr 2026 Modeyso commercial sales royalties Former Oncoceutics Inc. securityholdersHealthCare RoyaltyAsset saleAnnounced–Specialty finance and leasing+3 Latham & Watkins (sell-side)
Mar 2026 Apellis Pharmaceuticals –BiogenAcquisitionAnnounced5,600.0Biotech+2 Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side)
Mar 2026 Centessa Pharmaceuticals –Eli Lilly and CompanySchemePending6,300.0Biotech+1 Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Mar 2026 Kezar Life Sciences –Aurinia PharmaceuticalsAcquisitionAnnounced51.5Biotech+1 TD Securities (sell-side)Cooley (sell-side)
Mar 2026 AnaptysBio outstanding common stock –AnaptysBioBuy-backAnnounced100.0Biotech+1 Piper Sandler (buy-side)
Mar 2026 AZSTARYS business Corium Therapeutics HoldingsCollegium PharmaceuticalAsset salePending650.0Pharma Centerview Partners (sell-side)Sullivan & Cromwell (sell-side)Leerink Partners (buy-side)Goodwin (buy-side)
Mar 2026 Day One Biopharmaceuticals –ServierAcquisitionPending2,500.0Biotech+2 Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side)
Mar 2026 Corstasis Therapeutics –Esperion TherapeuticsAcquisitionCompleted75.0Pharma+1 PJT Partners (sell-side)Arnold & Porter (sell-side)Jefferies (buy-side)Gibson Dunn (buy-side)
Mar 2026 Transcend Therapeutics –OtsukaAcquisitionAnnounced700.0Biotech+2 Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side)
Mar 2026 Paratek Pharmaceuticals ––MergerCompleted–Pharma Skadden, Arps, Slate, Meagher & Flom
Mar 2026 Manufacturing facility in Phoenix, AZ Bristol Myers SquibbRoviAsset saleCompleted–Pharmaceutical Manufacturing+1 William Blair
Feb 2026 AiCuris Anti-infective Cures AG –Veloxis PharmaceuticalsAcquisitionAnnounced913.0Pharma+1 Gibson Dunn (sell-side)Freshfields (buy-side)
Feb 2026 Avadel Pharmaceuticals –AlkermesSchemeCompleted–Pharma+1 Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side)
Feb 2026 Orna Therapeutics –Eli Lilly and CompanyAcquisitionAnnounced2,400.0Biotech+1 Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side)
Jan 2026 TerSera Infusion Specialty Therapies Business Unit (IST) TerSera TherapeuticsESTEVEAsset salePending–Pharma Kirkland & Ellis (sell-side)Leerink Partners (sell-side)Perella Weinberg Partners (buy-side)Arnold & Porter (buy-side)

Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built